ArticleFrontiers in oncology2022

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series.

Shao Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.